Intermittent Versus Continuous Androgen Deprivation Therapy in Advanced Prostate Cancer

Reporting of Noninferiority and Equivalence Randomized Trials

(2013) Gilda Piaggio et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Intermittent versus Continuous Androgen Deprivation in Prostate Cancer

(2013) Maha Hussain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy

(2012) Juanita M. Crook et al.   NEW ENGLAND JOURNAL OF MEDICINE

Primary Intermittent Androgen Deprivation As Initial Therapy for Men with Newly Diagnosed Prostate Cancer

(2011) Mark C. Scholz et al.   Clinical Genitourinary Cancer

EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer

(2011) Nicolas Mottet et al.   EUROPEAN UROLOGY

A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study

(2011) J E Ward et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Does Local Treatment of the Prostate in Advanced and/or Lymph Node Metastatic Disease Improve Efficacy of Androgen-Deprivation Therapy? A Systematic Review

(2010) Paul C.M.S. Verhagen et al.   EUROPEAN UROLOGY

Duration of First Off-Treatment Interval Is Prognostic for Time to Castration Resistance and Death in Men With Biochemical Relapse of Prostate Cancer Treated on a Prospective Trial of Intermittent Androgen Deprivation

(2010) Evan Y. Yu et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study

(2009) Nigel A. Spry et al.   BJU INTERNATIONAL

Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?

(2009) Massimo Perachino et al.   BJU INTERNATIONAL

Intermittent Androgen Deprivation for Locally Advanced and Metastatic Prostate Cancer: Results from a Randomised Phase 3 Study of the South European Uroncological Group

(2009) Fernando E.C. Calais da Silva et al.   EUROPEAN UROLOGY

Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature

(2009) Per-Anders Abrahamsson   EUROPEAN UROLOGY

44 INTERMITTENT VERSUS CONTINUOUS MAXIMAL ANDROGEN BLOCKADE IN METASTATIC (D2) PROSTATE CANCER PATIENTS. A RANDOMIZED TRIAL

(2009) N. Mottet et al.   EUROPEAN UROLOGY SUPPLEMENTS

A Double-Blind Randomized Crossover Study of Oral Thalidomide Versus Placebo for Androgen Dependent Prostate Cancer Treated With Intermittent Androgen Ablation

(2009) William D. Figg et al.   JOURNAL OF UROLOGY

Decreasing Use of Luteinizing Hormone-Releasing Hormone Agonists in the United States is Independent of Reimbursement Changes: A Medicare and Veterans Health Administration Claims Analysis

(2009) Steven L. Chang et al.   JOURNAL OF UROLOGY

Quality of Life, Morbidity, and Mortality Results of a Prospective Phase II Study of Intermittent Androgen Suppression for Men with Evidence of Prostate-Specific Antigen Relapse After Radiation Therapy for Locally Advanced Prostate Cancer

(2008) Nicholas Bruchovsky et al.   Clinical Genitourinary Cancer

Finnish Multicenter Study Comparing Intermittent to Continuous Androgen Deprivation for Advanced Prostate Cancer: Interim Analysis of Prognostic Markers Affecting Initial Response to Androgen Deprivation

(2008) Arto J. Salonen et al.   JOURNAL OF UROLOGY

Etoricoxib and Intermittent Androgen Deprivation Therapy in Patients with Biochemical Progression After Radical Prostatectomy

(2008) Franco Di Silverio et al.   UROLOGY